本文選題：solithromycin + Ⅲ期臨床試驗(yàn)�。� 參考：《國際藥學(xué)研究雜志》2015年02期

【摘要】：正Cempra制藥公司宣布,其下一代大環(huán)內(nèi)酯類抗生素solithromycin口服膠囊,在1項(xiàng)用于社區(qū)獲得性細(xì)菌性肺炎(community acquired bacterial pneumonia,CABP)患者的全球多中心、雙盲、陽性藥對(duì)照的Ⅲ期臨床試驗(yàn)中,與拜耳公司的莫西沙星相比,達(dá)到非劣效的主要及次要目標(biāo)。這項(xiàng)Solitaire-Oral研究隨機(jī)入選
[Abstract]:Cempra Pharmaceuticals has announced that its next generation of macrolide antibiotics, solithromycin, was orally administered in a phase III clinical trial for patients with community-acquired bacterial pneumonia (community acquired bacterial pneumoniae) in a phase III clinical trial with double-blind, positive drug control. Compared with moxifloxacin of Bayer, the primary and secondary goals of non-inferior effect are achieved. The Solitaire-Oral study was randomly selected
【分類號(hào)】：R969.4

【相似文獻(xiàn)】

相關(guān)期刊論文 前1條

1 楊臻崢;;大環(huán)內(nèi)酯類抗生素Solithromycin[J];藥學(xué)進(jìn)展;2012年02期

，

本文編號(hào)：2116600